Avandia and Multihance drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Avandia (rosiglitazone maleate) and Multihance (gadobenate dimeglumine). Common drug interactions include nephrogenic systemic fibrosis among females and nephrogenic systemic fibrosis among males.

The phase IV clinical study analyzes what interactions people have when they take Avandia and Multihance. It is created by eHealthMe based on reports of 27 people who take the same drugs from the FDA, and is updated regularly.

What is Avandia?

Avandia has active ingredients of rosiglitazone maleate. It is often used in diabetes. eHealthMe is studying from 142,155 Avandia users. Check the latest studies of Avandia.

What is Multihance?

Multihance has active ingredients of gadobenate dimeglumine. eHealthMe is studying from 5,786 Multihance users. Check the latest studies of Multihance.

On Jul, 13, 2026

27 people who take Avandia and Multihance together, and have interactions are studied.

Avandia and Multihance drug interactions.

What are the common drug interactions of Avandia and Multihance, by gender? *:

female:

Nephrogenic systemic fibrosis (involves fibrosis of skin, joints, eyes due to kidney disease)
Pain
Pruritus (severe itching of the skin)
Skin discolouration (change of skin colour)
Skin induration (an abnormally hard spot or area on the skin)
Injury
Joint range of motion decreased (disease of joint movement)
Oedema peripheral (superficial swelling)
Skin tightness
Gait disturbance

male:

Nephrogenic systemic fibrosis (involves fibrosis of skin, joints, eyes due to kidney disease)
Skin tightness
Oedema peripheral (superficial swelling)
Skin fibrosis (fibrous tissue formation on skin)
Skin hypertrophy (skin cells enlarges)
Arthralgia (joint pain)
Asthenia (weakness)
Deformity (disfigurement)
Depression
Fibrosis (formation of excess fibrous connective tissue in an organ or tissue)

What are the common drug interactions of Avandia and Multihance, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

Acute myocardial infarction (acute heart attack)
Angina pectoris (chest pain due to ischemia of the heart muscle)
Arteriosclerosis coronary artery (thickening and hardening of arteries- coronary artery)
Laryngeal oedema (swelling of larynx)
Transient ischaemic attack (a transient episode of neurologic dysfunction caused by ischemia (loss of blood flow))
Urticaria (rash of round, red welts on the skin that itch intensely)

40-49:

n/a

50-59:

Nephrogenic systemic fibrosis (involves fibrosis of skin, joints, eyes due to kidney disease)
Pain
Skin tightness
Scar
Sensory loss (senses loss)
Injury
Anxiety
Emotional distress
Joint range of motion decreased (disease of joint movement)
Mobility decreased (ability to move is reduced)

60+:

Nephrogenic systemic fibrosis (involves fibrosis of skin, joints, eyes due to kidney disease)
Skin induration (an abnormally hard spot or area on the skin)
Deformity (disfigurement)
Scar
Skin hypertrophy (skin cells enlarges)
Skin fibrosis (fibrous tissue formation on skin)
Gait disturbance
Pruritus (severe itching of the skin)
Skin discolouration (change of skin colour)
Abdominal pain upper

What are the existing conditions these people have? *

Nuclear Magnetic Resonance Imaging Brain: 12 people, 44.44%
Nuclear Magnetic Resonance Imaging Abdominal: 5 people, 18.52%
Fluid Retention (an abnormal accumulation of fluid in the blood): 3 people, 11.11%
Dry Skin: 2 people, 7.41%
Cardiac Failure Chronic: 2 people, 7.41%
Blood Pressure Abnormal: 2 people, 7.41%
Blood Phosphorus Increased: 2 people, 7.41%
Anaemia (lack of blood): 2 people, 7.41%

* Approximation only. Some reports may have incomplete information.

Do you take Avandia and Multihance?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously